E-ISSN 1309-4866
Research Article
Intravenous Immunoglobulin Treatment for Recurrent Optic Neuritis
1 Department of Neurology, İstanbul Bilim University, İstanbul, Turkey  
2 Department of Neurology, Dokuz Eylül University School of Medicine, İzmir, Turkey  
3 Department of Ophthalmology, Dokuz Eylül University School of Medicine, İzmir, Turkey  
4 Department of Neurology, İstabul Dr. Sadi Konuk Training and Research Hospital, İstanbul, Turkey  
Arch Neuropsychiatry ; : -
DOI: 10.5152/npa.2017.20577
This article was viewed 53 times, downloaded 0 times

Key Words: Recurrent optic neuritis, neuromyelitis optica spectrum disorders, intravenous immunoglobulin

Introduction: Recurrent optic neuritis neuritis (rON) is an autoimmune inflammatory condition of unknown cause. Intravenous immunoglobulin (IVIg) treatment is used for many autoimmune disorders; however we do not have any information about its effect in rON, other than case reports. We aimed to evaluate our patients with rON who were treated with IVIg.


Methods: Data from all our patients with rON with or without anti aquaporin4 (AQP4) seropositivity, seen between April 2011 and October 2015, who received IVIg treatment were retrospectively evaluated.


Results: Nine patients (all female) with rON had received IVIg. These patients were aged between 34 and 65 years, and had started receiving monthly IVIg from 6 to 58 months after onset of disease. In three out of nine rON patients serum AQP4 antibody were positive. Under current treatments the patients had continued to have attacks, therefore monthly IVIg was given in addition to the existing immunosuppressant drug. The follow up duration was between 6 to 31 months. Three patients, each suffered one relapse under IVIg treatment. Mean number of relapses in the year prior to treatment was 1.4±0.72, whereas it was 0.3±0.5 during the year after IVIg therapy. During follow-up with IVIg administration only one patient had fever and no other adverse events were reported.


Conclusion: Monthly IVIg is well-tolerated and safe and it seems to be effective in rON as an add on treatment. However, since our study is a retrospective case series, future randomized controlled trials with IVIG are needed.

Key Words
Author's Corner
Latest Update: 29.12.2017